-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 23, Chongqing Gaojin Biotechnology Co.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
BNCT is one of the most advanced cancer treatment methods in the world.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
At present, the BPA boron drug codenamed "GJB01" of Gaojin Bio has completed the pharmaceutical research of raw materials and preparations, and completed the verification of the pilot scale preparation process.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
In March 2020, the world's first BNCT device and the world's first boron drug Steboronine were approved for marketing in Japan for use in unresectable locally advanced or locally recurrent head and neck cancer
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
GAO Jin, deputy general manager of biological and project leader Cai Shaohui representation, "GJB01" the overall index and the Japanese market Steboronine drugs exactly the same, and more cost-effective, are expected in 2023 for clinical BNCT cancer is expected to become China's first listed Boron medicine
.
.
Cai Shaohui said, “There is no doubt about the advanced nature of BNCT treatment.
The core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
The core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
"BNCT therapy can be called cancer treatment' crown due to its low cost, short course of treatment (30 minutes to 60 minutes each time, and only one to two treatments at the fastest), wide indications, and low side effects.
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
On November 23, Chongqing Gaojin Biotechnology Co.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
BNCT is one of the most advanced cancer treatment methods in the world.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
At present, the BPA boron drug codenamed "GJB01" of Gaojin Bio has completed the pharmaceutical research of raw materials and preparations, and completed the verification of the pilot scale preparation process.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
In March 2020, the world's first BNCT device and the world's first boron drug Steboronine were approved for marketing in Japan for use in unresectable locally advanced or locally recurrent head and neck cancer
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
GAO Jin, deputy general manager of biological and project leader Cai Shaohui representation, "GJB01" the overall index and the Japanese market Steboronine drugs exactly the same, and more cost-effective, are expected in 2023 for clinical BNCT cancer is expected to become China's first listed Boron medicine
.
.
Cai Shaohui said, “There is no doubt about the advanced nature of BNCT treatment.
The core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
The core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
"BNCT therapy can be called cancer treatment' crown due to its low cost, short course of treatment (30 minutes to 60 minutes each time, and only one to two treatments at the fastest), wide indications, and low side effects.
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
On November 23, Chongqing Gaojin Biotechnology Co.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
, Ltd.
(hereinafter referred to as "Gaojin Bio") of the National Biological Industry Base of Chongqing High-tech Zone announced that it has successfully developed the first melanoma and brain cancer based on the non-radioactive isotope boron-10.
, BPA boron drugs for malignant tumors such as glioma, through BNCT (Boron Neutron Capture Therapy) can cure a variety of specific cancers in as fast as 30 minutes
.
BNCT is one of the most advanced cancer treatment methods in the world.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
It destroys cancer cells through nuclear reactions in tumor cells
.
Its treatment principle is: first inject a non-toxic and harmless boron-containing drug into the patient.
After the drug enters the human body, it quickly targets and accumulates in specific cancer cells
.
At this time, it is irradiated with a neutron beam that does not cause much damage to the human body.
After the neutron collides with the boron that enters the cancer cell, a strong "nuclear reaction" is generated, and a heavy ion beam with strong lethality is released.
The range of the rays is very short and can only kill cancer cells without damaging surrounding tissues
.
This selective targeted radiotherapy technique that only kills cancer cells without damaging normal tissues is called boron neutron capture therapy
.
At present, the BPA boron drug codenamed "GJB01" of Gaojin Bio has completed the pharmaceutical research of raw materials and preparations, and completed the verification of the pilot scale preparation process.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
It can be used in the R&D institutions of major BNCT neutron therapy devices in China to carry out related research experiments and Clinical application
.
It is worth noting that pilot production is a necessary link for the transformation of scientific and technological achievements into productivity, and the success or failure of the industrialization of results mainly depends on the success or failure of the pilot production
.
In March 2020, the world's first BNCT device and the world's first boron drug Steboronine were approved for marketing in Japan for use in unresectable locally advanced or locally recurrent head and neck cancer
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
.
In addition, hundreds of clinical trials have been conducted for brain tumors, malignant melanoma, lung cancer, pleural mesothelioma, liver cancer, breast cancer, etc.
, and good cure data have been obtained
.
GAO Jin, deputy general manager of biological and project leader Cai Shaohui representation, "GJB01" the overall index and the Japanese market Steboronine drugs exactly the same, and more cost-effective, are expected in 2023 for clinical BNCT cancer is expected to become China's first listed Boron medicine
.
Medicine, medicine, medicine.
Cai Shaohui said, “There is no doubt about the advanced nature of BNCT treatment.
The core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
Tumor tumor tumorThe core key lies in boron medicine.
Gao Jin Bio’s goal is to make China’s BNCT treatment reach the world’s leading level, and the treatment cost can be effectively controlled at around RMB 100,000, so that cancer patients There is law to cure, and money to cure
.
"
"BNCT therapy can be called cancer treatment' crown due to its low cost, short course of treatment (30 minutes to 60 minutes each time, and only one to two treatments at the fastest), wide indications, and low side effects.
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
"The pearl of life'
.
" Gao Jin Bio CEO Wang Jian said that the most important thing is the targeting and preparation process of the boron drug, which determines whether the therapy can better and accurately treat more types of cancer
.
(over)
